Cited by 11Pancreatic function and diabetesDiabetes and associated disordersGenomics and Rare Diseases

Case Report: Hypoglycemia Due to a Novel Activating Glucokinase Variant in an Adult – a Molecular Approach

Open access
Koneshamoorthy, Anojian, Seniveratne-Epa, Dilan, Calder, Genevieve, Sawyer, Matthew, Kay, Thomas W. H., Farrell, Stephen, Loudovaris, Thomas, Mariana, Lina +13 more·2022·Frontiers in Endocrinology

Abstract

We present a case of an obese 22-year-old man with activating GCK variant who had neonatal hypoglycemia, re-emerging with hypoglycemia later in life. We investigated him for asymptomatic hypoglycemia with a family history of hypoglycemia. Genetic testing yielded a novel GCK missense class 3 variant that was subsequently found in his mother, sister and nephew and reclassified as a class 4 likely pathogenic variant. Glucokinase enables phosphorylation of glucose, the rate-limiting step of glycolysis in the liver and pancreatic β cells. It plays a crucial role in the regulation of insulin secretion. Inactivating variants in GCK cause hyperglycemia and activating variants cause hypoglycemia. Spleen-preserving distal pancreatectomy revealed diffuse hyperplastic islets, nuclear pleomorphism and periductular islets. Glucose stimulated insulin secretion revealed increased insulin secretion in response to glucose. Cytoplasmic calcium, which triggers exocytosis of insulin-containing granules, revealed normal basal but increased glucose-stimulated level. Unbiased gene expression analysis using 10X single cell sequencing revealed upregulated INS and CKB genes and downregulated DLK1 and NPY genes in β-cells. Further studies are required to see if alteration in expression of these genes plays a role in the metabolic and histological phenotype associated with glucokinase pathogenic variant. There were more large islets in the patient’s pancreas than in control subjects but there was no difference in the proportion of β cells in the islets. His hypoglycemia was persistent after pancreatectomy, was refractory to diazoxide and improved with pasireotide. This case highlights the variable phenotype of GCK mutations. In-depth molecular analyses in the islets have revealed possible mechanisms for hyperplastic islets and insulin hypersecretion.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2022.842937

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Experimental evidence suggests that higher basal insulin secretion and changes in the resting membrane potential of β-cells might contribute to the biochemical and clinical findings of adult NIPHS.

    “Some experimental evidence suggests that a higher basal insulin secretion, as well as changes in the resting membrane potential of β -cells, might contribute to the biochemical and clinical findings of the disease [50-52].”

    From An Uncommon Cause of Recurrent Presyncope, Dizziness, and Tachycardia: A Case Report of Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) (2023) · cites this paper as [52]

    The Results (Pancreatic Islet Analysis; page unavailable) report higher glucose-stimulated insulin secretion in the patient’s islets, and the Discussion links altered β-cell function to a lower threshold for insulin release. The copy does not establish higher basal insulin secretion or report changes in resting membrane potential; its basal calcium measurement showed no significant difference. The evidence comes from one adult with an activating glucokinase variant, not adult NIPHS generally. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Stimulation of somatostatin receptors by octreotide, lanreotide, or pasireotide has repeatedly been described in the literature in the context of NIPHS.

    “The stimulation of somatostatin receptors by octreotide, lanreotide, or pasireotide has also repeatedly been described in the literature in the context of NIPHS.”

    From An Uncommon Cause of Recurrent Presyncope, Dizziness, and Tachycardia: A Case Report of Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) (2023) · cites this paper as [52]

    The Introduction’s Clinical Case section (page unavailable) describes octreotide and pasireotide as somatostatin analogues that activate specified somatostatin receptors. It reports their use in one patient with hypoglycemia due to a glucokinase variant, but does not mention lanreotide or establish that receptor stimulation by these drugs has repeatedly been described in NIPHS. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Because somatostatin analogues also inhibit glucagon secretion, symptoms of hypoglycemia may occur even more frequently in a subset of NIPHS patients.

    “Since these substances also inhibit the secretion of glucagon, symptoms of hypoglycemia may occur even more frequently in a subset of patients [52,61,62].”

    From An Uncommon Cause of Recurrent Presyncope, Dizziness, and Tachycardia: A Case Report of Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) (2023) · cites this paper as [52]

    The Clinical Case section reports that octreotide did not improve one patient’s hypoglycemia, while pasireotide improved it. Searches for glucagon inhibition and worsening hypoglycemia found no passage linking somatostatin analogues to more frequent hypoglycemia in a subset of patients. The copy also does not identify the patient as having NIPHS. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 36

  1. [1]Irwin DM Tan H. Evolution of Glucose Utilization: Glucokinase and Glucokinase Regulator Protein. Mol Phylogenet Evol (2014) 70: 195– 203. doi: 10.1016/j.ympev.2013.09.016 24075984 PMC3897444 · DOI
  2. [2]Matschinsky FM. Glucokinase as Glucose Sensor and Metabolic Signal Generator in Pancreatic Beta-Cells and Hepatocytes. Diabetes (1990) 39: 647–52. doi: 10.2337/diabetes.39.6.647 2189759 · DOI
  3. [3]Sternisha SM Miller BG. Molecular and Cellular Regulation of Human Glucokinase. Arch Biochem Biophys (2019) 663: 199– 213. doi: 10.1016/j.abb.2019.01.011 30641049 PMC6377845 · DOI
  4. [4]Froguel P Zouali H Vionnet N Velho G Vaxillaire M Sun F. Familial Hyperglycemia Due to Mutations in Glucokinase. Definition of a Subtype of Diabetes Mellitus. New Engl J Med (1993) 328: 697– 702. doi: 10.1056/NEJM199303113281005 8433729 · DOI
  5. [5]Glaser B Kesavan P Heyman M Davis E Cuesta A Buchs A. Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation. New Engl J Med (1998) 338: 226–30. doi: 10.1056/NEJM199801223380404 9435328 · DOI
  6. [6]Draznin B. Intracellular Calcium, Insulin Secretion, and Action. Am J Med (1988) 85: 44– 58. doi: 10.1016/0002-9343(88)90397-X 3057895 · DOI
  7. [7]Kassem S Bhandari S Rodriguez-Bada P Motaghedi R Heyman M Garcia-Gimeno MA. Large Islets, Beta-Cell Proliferation, and a Glucokinase Mutation. New Engl J Med (2010) 362: 1348–50. doi: 10.1056/NEJMc0909845 20375417 · DOI
  8. [8]Rodnoi P Rajkumar M Moin ASM Georgia SK Butler AE Dhawan S. Neuropeptide Y Expression Marks Partially Differentiated Beta Cells Mice Humans. JCI Insight (2017) 2(12): e94005. doi: 10.1172/jci.insight.94005 PMC5470892 28614797 · DOI
  9. [9]Martens GA Motte E Kramer G Stange G Gaarn LW Hellemans K. Functional Characteristics of Neonatal Rat Beta Cells With Distinct Markers. J Mol Endocrinol (2014) 52: 11– 28. doi: 10.1530/JME-13-0106 24049066 · DOI
  10. [10]Johnson JD Bernal-Mizrachi E Alejandro EU Han Z Kalynyak TB Li H. Insulin Protects Islets From Apoptosis via Pdx1 and Specific Changes in the Human Islet Proteome. Proc Natl Acad Sci United States America (2006) 103: 19575–80. doi: 10.1073/pnas.0604208103 PMC1748267 17158802 · DOI
  11. [11]Alejandro EU Kalynyak TB Taghizadeh F Gwiazda KS Rawstron EK Jacob KJ. Acute Insulin Signaling in Pancreatic Beta-Cells Is Mediated by Multiple Raf-1 Dependent Pathways. Endocrinology (2010) 151: 502–12. doi: 10.1210/en.2009-0678 PMC2817610 20056832 · DOI
  12. [12]Kulkarni RN Bruning JC Winnay JN Postic C Magnuson MA Kahn CR. Tissue-Specific Knockout of the Insulin Receptor in Pancreatic Beta Cells Creates an Insulin Secretory Defect Similar to That in Type 2 Diabetes. Cell (1999) 96: 329–39. doi: 10.1016/S0092-8674(00)80546-2 10025399 · DOI
  13. [13]Kim MH Hong SH Lee MK. Insulin Receptor-Overexpressing Beta-Cells Ameliorate Hyperglycemia in Diabetic Rats Through Wnt Signaling Activation. PloS One (2013) 8: e67802. doi: 10.1371/journal.pone.0067802 23874448 PMC3706479 · DOI
  14. [14]Ansarullah C Jain FF Far S Homberg K Wissmiller FG von Hahn A. Inceptor Counteracts Insulin Signalling in Beta-Cells to Control Glycaemia. Nature (2021) 590: 326–31. doi: 10.1038/s41586-021-03225-8 33505018 · DOI
  15. [15]Morishita K Kyo C Yonemoto T Kosugi R Ogawa T Inoue T. Asymptomatic Congenital Hyperinsulinism Due to a Glucokinase-Activating Mutation, Treated as Adrenal Insufficiency for Twelve Years. Case Rep Endocrinol (2017) 2017: 4709262. doi: 10.1155/2017/4709262 28163940 PMC5253496 · DOI
  16. [16]Postic C Shiota M Niswender KD Jetton TL Chen Y Moates JM. Dual Roles for Glucokinase in Glucose Homeostasis as Determined by Liver and Pancreatic Beta Cell-Specific Gene Knock-Outs Using Cre Recombinase. J Biol Chem (1999) 274: 305–15. doi: 10.1074/jbc.274.1.305 9867845 · DOI · Paper page
  17. [17]Ping F Wang Z Xiao X. Clinical and Enzymatic Phenotypes in Congenital Hyperinsulinemic Hypoglycemia Due to Glucokinase-Activating Mutations: A Report of Two Cases and a Brief Overview of the Literature. J Diabetes Investig (2019) 10: 1454–62. doi: 10.1111/jdi.13072 PMC6825936 31094068 · DOI
  18. [18]Challis BG Harris J Sleigh A Isaac I Orme SM Seevaratnam N. Familial Adult Onset Hyperinsulinism Due to an Activating Glucokinase Mutation: Implications for Pharmacological Glucokinase Activation. Clin Endocrinol (2014) 81: 855–61. doi: 10.1111/cen.12517 PMC4735948 24890200 · DOI
  19. [19]Gilis-Januszewska A Boguslawska A Kowalik A Rzepka E Soczowka K Przybylik-Mazurek E. Hyperinsulinemic Hypoglycemia in Three Generations of a Family With Glucokinase Activating Mutation, C.295T>C (P.Trp99Arg). Genes (Basel) (2021) 12. doi: 10.3390/genes12101566 PMC8535713 34680961 · DOI
  20. [20]Bouche C Lopez X Fleischman A Cypess AM O’Shea S Stefanovski D. Insulin Enhances Glucose-Stimulated Insulin Secretion in Healthy Humans. Proc Natl Acad Sci United States America (2010) 107: 4770–5. doi: 10.1073/pnas.1000002107 PMC2842068 20176932 · DOI
  21. [21]Aspinwall CA Qian WJ Roper MG Kulkarni RN Kahn CR Kennedy RT. Roles of Insulin Receptor Substrate-1, Phosphatidylinositol 3-Kinase, and Release of Intracellular Ca2+ Stores in Insulin-Stimulated Insulin Secretion in Beta -Cells. J Biol Chem (2000) 275: 22331–8. doi: 10.1074/jbc.M909647199 10764813 · DOI
  22. [22]Roper MG Qian WJ Zhang BB Kulkarni RN Kahn CR Kennedy RT. Effect of the Insulin Mimetic L-783,281 on Intracellular Ca2+ and Insulin Secretion From Pancreatic Beta-Cells. Diabetes (2002) 51(Suppl 1): S43–9. doi: 10.2337/diabetes.51.2007.S43 11815457 · DOI
  23. [23]Carlsson C Tornehave D Lindberg K Galante P Billestrup N Michelsen B. Growth Hormone and Prolactin Stimulate the Expression of Rat Preadipocyte Factor-1/Delta-Like Protein in Pancreatic Islets: Molecular Cloning and Expression Pattern During Development and Growth of the Endocrine Pancreas. Endocrinology (1997) 138: 3940–8. doi: 10.1210/endo.138.9.5408 9275085 · DOI
  24. [24]Friedrichsen BN Carlsson C Moldrup A Michelsen B Jensen CH Teisner B. Expression, Biosynthesis and Release of Preadipocyte Factor-1/Delta-Like Protein/Fetal Antigen-1 in Pancreatic Beta-Cells: Possible Physiological Implications. J Endocrinol (2003) 176: 257–66. doi: 10.1677/joe.0.1760257 12553874 · DOI
  25. [25]Abdallah BM Ditzel N Laborda J Karsenty G Kassem M. DLK1 Regulates Whole-Body Glucose Metabolism: A Negative Feedback Regulation of the Osteocalcin-Insulin Loop. Diabetes (2015) 64: 3069–80. doi: 10.2337/db14-1642 25918236 · DOI
  26. [26]Appelbe OK Yevtodiyenko A Muniz-Talavera H Schmidt JV. Conditional Deletions Refine the Embryonic Requirement for Dlk1. Mech Dev (2013) 130: 143–59. doi: 10.1016/j.mod.2012.09.010 PMC3570732 23059197 · DOI
  27. [27]Gomes LG Cunha-Silva M Crespo RP Ramos CO Montenegro LR Canton A. DLK1 is a Novel Link Between Reproduction and Metabolism. J Clin Endocrinol Metab (2019) 104: 2112–20. doi: 10.1210/jc.2018-02010 30462238 · DOI
  28. [28]Moon YS Smas CM Lee K Villena JA Kim KH Yun EJ. Mice Lacking Paternally Expressed Pref-1/Dlk1 Display Growth Retardation and Accelerated Adiposity. Mol Cell Biol (2002) 22: 5585–92. doi: 10.1128/MCB.22.15.5585-5592.2002 PMC133956 12101250 · DOI
  29. [29]Barbaro B Salehi P Wang Y Qi M Gangemi A Kuechle J. Improved Human Pancreatic Islet Purification With the Refined UIC-UB Density Gradient. Transplantation (2007) 84: 1200–3. doi: 10.1097/01.tp.0000287127.00377.6f 17998877 · DOI
  30. [30]Lund SP Nettleton D McCarthy DJ Smyth GK. Detecting Differential Expression in RNA-Sequence Data Using Quasi-Likelihood With Shrunken Dispersion Estimates. Stat Appl Genet Mol Biol (2012) 11. doi: 10.1515/1544-6115.1826 23104842 · DOI
  31. [33]Lun AT McCarthy DJ Marioni JC. A Step-by-Step Workflow for Low-Level Analysis of Single-Cell RNA-Seq Data With Bioconductor. F1000Res (2016) 5: 2122. doi: 10.12688/f1000research.9501.2 27909575 PMC5112579 · DOI
  32. [34]Segerstolpe A Palasantza A Eliasson P Andersson EM Andreasson AC Sun X. Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes. Cell Metab (2016) 24: 593– 607. doi: 10.1016/j.cmet.2016.08.020 27667667 PMC5069352 · DOI · Paper page
  33. [35]McCarthy DJ Chen Y Smyth GK. Differential Expression Analysis of Multifactor RNA-Seq Experiments With Respect to Biological Variation. Nucleic Acids Res (2012) 40: 4288–97. doi: 10.1093/nar/gks042 PMC3378882 22287627 · DOI · Paper page
  34. [36]Soneson C Robinson MD. Bias, Robustness and Scalability in Single-Cell Differential Expression Analysis. Nat Methods (2018) 15: 255–61. doi: 10.1038/nmeth.4612 29481549 · DOI · Paper page
  35. [37]Parkash J Chaudhry MA Amer AS Christakos S Rhoten WB. Intracellular Calcium Ion Response to Glucose in Beta-Cells of Calbindin-D28k Nullmutant Mice and in Betahc13 Cells Overexpressing Calbindin-D28k. Endocrine (2002) 18: 221–9. doi: 10.1385/ENDO:18:3:221 12450313 · DOI
  36. [38]Low JT Shukla A Behrendorff N Thorn P. Exocytosis, Dependent on Ca2+ Release From Ca2+ Stores, Is Regulated by Ca2+ Microdomains. J Cell Sci (2010) 123: 3201–8. doi: 10.1242/jcs.071225 20736314 · DOI

Cited by

Sorted by citations

Authors
Koneshamoorthy, A., Seniveratne-Epa, D., Calder, G., Sawyer, M., Kay, T. W. H., Farrell, S., Loudovaris, T., Mariana, L., McCarthy, D., Lyu, R., Liu, X., Thorn, P., Tong, J., Chin, L. K., Zacharin, M., Trainer, A., Taylor, S., MacIsaac, R. J., Sachithanandan, N., Thomas, H. E., & Krishnamurthy, B.
Affiliations
  • St Vincent's Hospital Melbourne (AU)
  • St Vincents Institute of Medical Research (AU)
  • The University of Melbourne (AU)
  • The University of Sydney (AU)
  • Royal Children's Hospital (AU)
  • The Royal Melbourne Hospital (AU)
Corresponding author
Krishnamurthy, Balasubramanian
Venue
Frontiers in Endocrinology
Published
2022-03-17
Volume
13
Pages
842937-842937
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4220950949
Cited by
11
References
2
Citations by year
2024: 1 · 2023: 9 · 2022: 1
FWCI
2.63
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
glucokinase, activating mutations, neonatal hypoglycemia, insulin hypersecretion, glucose-stimulated insulin secretion, pancreatic beta cells, pasireotide, diazoxide, variable phenotype, single-cell RNA sequencing
MeSH terms
Insulin Secretion, Adult, Glucokinase, Glucose, Humans, Hypoglycemia, Insulin, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review